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ABSTRACT
Background/aims The receptor for advanced glycation
end-products (RAGE) has been implicated in the
pathogenesis of diabetic microvascular complications.
The aim of this study was to investigate the association
between 2245G/A gene polymorphism of the RAGE
gene and retinopathy in Malaysian type 2 diabetic
patients.
Methods 342 unrelated type 2 diabetic patients (171
with retinopathy (DR), 171 without retinopathy (DNR))
and 235 unrelated healthy subjects from all over
Malaysia were recruited for this study. Genomic DNA
was isolated from 3 ml samples of whole blood using
a modiﬁed conventional DNA extraction method. The
genotype and allele frequencies of 2245G/A were
studied using the polymerase chain reactionerestriction
fragment length polymorphism (PCR-RFLP) method.
Results A statistically signiﬁcant difference in 2245A
minor allele frequency was found between control (5.5%)
and DR groups (15.2%) (p<0.001, OR¼3.06, 95% CI
1.87 to 5.02) as well as between DNR (8.2%) and DR
(15.2%) groups (p<0.01, OR¼2.01, 95% CI 1.24 to
3.27). However, when the frequency was compared
between control and DNR groups, there was no
signiﬁcant difference (p>0.05).
Conclusions This is the ﬁrst study that shows an
association between the 2245A allele of the RAGE gene
and development of diabetic retinopathy in the Malaysian
population.
INTRODUCTION
Retinopathy is the second leading cause of vision
loss due to the degeneration of the retina and
affects the quality of life of type 2 diabetic
patients.
1 A number of studies have attempted to
identify genes and their variants that are associated
with retinopathy across different populations, and
this includes the gene encoding the receptor for
advanced glycation end-products (RAGE). RAGE is
a multi-ligand member of the immunoglobulin
superfamily of cell surface molecules, and RAGE
gene is located on chromosome 6p21.3 at the major
histocompatibility complex locus in the class III
region and composed of 11 exons as well as
a3 9 UTR.
2 RAGE has been shown by in vivo and in
vitro studies to play a role in the pathogenesis of
diabetic microvascular complications.
3
RAGE recognises a wide range of endogenous
ligands including advanced glycation end-products
(AGE) and its expression is upregulated in patients
with retinopathy.
4 AGE are complex, heterogenous
molecules formed from non-enzymatic glycation
and oxidation of protein, lipids and nucleic acids.
56
A serious consequence of AGE formation is their
sustained interaction with RAGE, which leads to
a positive feedback loop that enhances the expres-
sion of RAGE in the retina. This activates the
proinﬂammatory transcription factor nuclear
factor-kB (NF-kB), which causes deleterious
effects.
5e8 Genetic polymorphism in RAGE could
alter this sequence of events by changing the
expression of RAGE and thereby affect the course
of the disease.
Most of the RAGE polymorphisms that have
been identiﬁed comprise either rare coding changes
or are located in non-coding regions.
9 10 2245G/A
RAGE polymorphism, situated at intron 8 region,
is of interest due to its relatively high prevalence,
and the nucleotide change can be rapidly screened
using the polymerase chain reactionerestriction
fragment length polymorphism (PCR-RFLP)
method. Only a few studies have investigated the
relationship between this polymorphism and dia-
betic retinopathy (DR) and these were carried out
in limited populations. However, no positive
association data have been reported.
11 In this
study, we aimed to investigate the association
of 2245G/A RAGE gene polymorphisms with
retinopathy in the Malaysian type 2 diabetic
population.
MATERIALS AND METHODS
Sample collection
The study sample was recruited from a pool of
diabetic patients referred by the Diabetic Clinic for
eye examination at the Ophthalmology Clinic in
the University Malaya Medical Centre (UMMC),
Malaysia. Patients with type 1 or type 2 diabetes
with less than 1 year duration of retinopathy were
excluded from the study. A total of 342 unrelated
consecutive type 2 diabetic patients (with and
without retinopathy) (198 men, 144 women) aged
57.969.8 years (mean6SD; range 35 to 79 years)
were recruited for this study. Detailed medical
and ophthalmologic histories as well as socio-
demographic factors and lifestyle variables were
noted. All previous ophthalmologic procedures,
including panretinal laser photocoagulation and/or
pars plana vitrectomy, were recorded.
Six ml of blood was obtained from each subject
for the single nucleotide polymorphism (SNP)
study. Three ml of the blood was sent for routine
blood examination in Clinical Diagnostic
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Laboratory scienceLaboratory at the University Malaya Medical Centre. All the
patients underwent a complete eye examination that included
dilated retinal examination and seven-ﬁeld stereoscopic Diabetic
Retinopathy Study retinal photography.
12 The colour fundus
photographs were graded for DR severity in a masked fashion by
two independent ophthalmologists at University of Malaya Eye
Research Center in Kuala Lumpur. The modiﬁed Early Treatment
of Diabetic Retinopathy Study Airlie House classiﬁcation of DR
was used to grade the retinopathy into the following categories:
mild non-proliferative retinopathy (mild NPDR), moderate non-
proliferative retinopathy (moderate NPDR), severe non-prolif-
erative retinopathy (severe NPDR) and proliferative retinopathy
(PDR).
13 14
Among the 342 recruited diabetic patients, 171 patients were
without retinopathy (DNR) and 171 with retinopathy (DR).
Among the DR patients, there were 27 mild NPDR patients, 72
moderate NPDR patients, nine severe NPDR patients and 63
PDR patients. The non-retinopathy controls were recruited from
volunteer blood donors. They consisted of 235 unrelated healthy
subjects (134 men, 101 women) aged 52.263.6 years
(mean6SD; range 44e59 years).
Genotyping
Genomic DNA from the control subjects and the patients was
isolated from 3 ml of peripheral blood by a modiﬁed conven-
tional DNA extraction method as used in previous study.
15 16 It
is noteworthy that the 2245G/A polymorphism (rs55640627)
was the only SNP investigated in this study. This SNP was
detected using PCR-RFLP. PCR was used to amplify the intron 8
region containing this polymorphism as described previously.
10
In brief, a two-step nested PCR was used since this poly-
morphism lies in a highly homologous region. In silico PCR as
described previously was applied in this study to make sure the
primers were targeted to the correct loci prior to the actual
PCR.
17e19 In the ﬁrst PCR, the forward primer 59 GCC CCA
TTC TGG CCT TAT CCC TAA 39 and reverse primer 59 CCA
CCA TGC CTG GCT AAT TTT GT 39 were used to amplify
a 294 bp product in a ﬁnal PCR mixture of 15 ml containing
100 ng of genomic DNA and 12.5 pmol of each primer. The
DNA was then subjected to initial denaturation at 958C for
3 min, followed by 30 cycles of denaturation at 948C for 15 s,
annealing and elongation at 608C for 30 s, and a ﬁnal extension
at 728C for 8 min. A sample of the ampliﬁed product (10 ml) was
diluted with 500 ml of sterile distilled water and 1 ml was used for
the second PCR. The second PCR was performed using the
former reverse primer and a speciﬁc ampliﬁcation-created
restriction site forward primer (59ACA CTT TGG GAG GCT
GCT GC 39)i naﬁnal volume of 20 ml to amplify a 116 bp
product. The PCR amplicon was subjected to an initial dena-
turation (958C for 3 min), followed by ampliﬁcation comprising
of 40 cycles, with each cycle consisting of a sequence of
temperatures set at 948C for 10 s, 56.78C for 20 s and 728C for
20 s, followed by a ﬁnal extension at 728C for 8 min.
Restriction endonuclease digestion and sequencing
The change of nucleotide (guanine to adenine) at intron 8 region
creates a PstI restriction site (CTGCA/G). Restriction analysis
was performed with PCR products digested overnight with ﬁve
units of restriction nuclease PstI (MBI Fermentas, Vilnius,
Lithuania) at 378C. The digested products were immediately
separated by electrophoresis in 3% (w/v) agarose gel with
ethidium bromide and visualised under UV. Subsequent digestion
with PstI revealed fragments of 95 bp and 21 bp for the mutated
minor allele 2245A. The wild-type major allele 2245G was 116 bp
long since it does not carry the restriction site (ﬁgure 1).
Five representative samples from each genotype were further
sequenced to conﬁrm the overall genotyping results.
Statistical analysis
The unpaired t test and one-way analysis of variance (ANOVA)
with Tukey’s post hoc test were used for the evaluation of
differences in biochemical variables among the groups. For the
evaluation of gene polymorphism, HardyeWeinberg equilibrium
and dichotomous variables were examined in the studied groups
using c
2 test with one degree of freedom.
20 The statistical
signiﬁcance of differences in allele frequencies among the three
groups was tested by two-tailed Fisher’s exact test. For each OR,
95% CI was calculated. A p value <0.05 was considered to be
statistically signiﬁcant. GraphPad Prism for Windows V.5.02
(GraphPad Software Inc., La Jolla, San Diego, California, USA)
was used for all statistical analyses.
RESULTS
The demographic data for the healthy controls, and the DNR
and DR patients, are shown in table 1. Both DNR and DR
patients had signiﬁcantly (p<0.05) higher levels of glycated
haemoglobin (HbA1c), total cholesterol, high-density lipoprotein
and low-density lipoprotein, and higher systolic blood pressure
and frequency of hypertension than healthy controls. Compar-
ison between the DNR and DR groups showed that patients in
the DR group were younger, had higher levels of HbA1c and total
cholesterol, had longer diabetes duration and were less likely to
be smokers (all p<0.05). No signiﬁcant differences (p>0.05)
were observed in body mass index, levels of triglyceride, alanine
aminotransferase and aspartate aminotransferase, diastolic blood
pressure, the number of subjects with alcohol intake, and the
number of subjects with hypertension.
Genotype distribution and allele frequency of 2245G/A poly-
morphism in the healthy controls, and DNR and DR groups are
shown in table 2. The distribution of the genotype did not
deviate from the HardyeWeinberg equilibrium in any of the
groups except for the DR group. The gene and allele frequencies
for 2245G/A polymorphism were GG 88.9%, GA 11.1%, AA 0%
(G 94.5%, A 5.5%) for the healthy control group, GG 83.6%, GA
16.4%, AA 0% (G 91.8%, A 8.2%) for the DNR group, and GG
Figure 1 Digested polymerase chain reaction (PCR) products of 2245
RAGE gene intron region. Lane 1: a 50 bp DNA ladder; lane 2: DNA blank;
lanes 3e5: ﬁrst-step PCR product (294 bp), wild-type homozygote for
2245GG (116 bp) and heterozygote for 2245GA (116 bp and 95 bp).
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Our study did not detect 2245AA minor genotype in any of the
groups. A statistically signiﬁcant difference in 2245A minor
allele frequency was found between the control (5.5%) and DR
(15.2%) groups (p<0.001, OR¼3.06, 95% CI 1.87 to 5.02) as well
as between the DNR (8.2%) and DR (15.2%) groups (p<0.01,
OR¼2.01, 95% CI 1.24 to 3.27). However, when control and
DNR groups were compared, there was no signiﬁcant difference
(p>0.05).
DISCUSSION
Muller cells regulate some important features of early retinal
vascular damage in DR, such as vascular permeability and
homeostasis.
21 The role of RAGE in the pathogenesis of diabetic-
related eye complication was supported by a recent ﬁnding of
predominant expression of RAGE in the retinal glia (Muller cells)
of diabetic rats compared with non-diabetic rats.
21 The accu-
mulation of AGE in an individual could increase the retinal
endothelial cell permeability causing vascular leakage. Certain
cytokines, such as vascular endothelial growth factor, could be
induced through the AGEeRAGE interaction, leading to
neovascularisation and angiogenesis that could result in reti-
nopathy.
22 Soluble RAGE (sRAGE) is a naturally occurring
inhibitor of signalling pathways induced by RAGE as it can
remove AGE by acting as a decoy and blocking the AGEeRAGE
interaction.
23 A critical event in the pathogenesis of diabetic
retinopathy is the inappropriate adherence of leucocytes to the
retinal capillaries.
7 In 2003, Moore et al showed that sRAGE was
able to reduce AGE-induced leucocyte adhesion to endothelial
cell monolayers.
7
Although the functional effect of the intronic polymorphism
is unknown, the possibility of its quantitative impact on RAGE
expression should not be ruled out. sRAGE is produced by
alternative splicing of RAGE mRNA, which involves regions
between intron 7 and 9.
24 The intron 8 region in which the
2245G/A polymorphism is present could hypothetically be
involved in this regulatory process. The level of sRAGE has been
shown to be signiﬁcantly reduced in diabetic retinopathy
patients compared with healthy controls.
23e25 Kankova et al
performed a pilot study in 2002 by investigating the relationship
of three RAGE intron polymorphisms with diabetic retinopathy
in Caucasians.
11 They reported that intron polymorphism
2245G/A was probably not involved in the genetic modiﬁcation
of susceptibility to the development of proliferative diabetic
retinopathy.
In this study, we found that 2245A minor allele was signiﬁ-
cantly present (p<0.001) in the DR group (15.2%) compared
with the DNR group (8.2%) (table 2). We hypothesise that
individuals with increased 2245A allele frequency could have
greater AGEeRAGE interaction due to low sRAGE level and
a higher risk of developing retinopathy. This genetic predispo-
sition is probably independent of diabetes itself. However, the
actual mechanism of how it affects the disease development
still needs to be shown in functional studies. It is possible that
the effect of 2245A allele may be related to linkage disequilib-
rium with a nearby causative factor that was not investigated
in this study. The negative ﬁnding by Kankova et al
11 could be
due to small sample size of Caucasian DR patients (n¼75); the
study lacked power and this could have led to a false-negative
result. Differences in genetic background and population
history may also contribute to this contradictory ﬁnding.
Recently, Balasubbu et al reported that another RAGE gene
polymorphism, Gly82Ser, was associated with DR in south
Indians.
26 However, this polymorphism is not likely to be in
linkage disequilibrium with the 2245G/A polymorphism since
it was reported as a low risk allele for DR in south Indians
26 and
the population histories of south Indians and Malaysians are
different.
In conclusion, although a recent study reported that Gly82Ser,
1704G/Tand 2184A/G polymorphisms in the RAGE gene are not
involved in the development of retinopathy in the Malaysian
population,
27 this is the ﬁrst study showing that 2245A allele of
RAGE gene is associated with the development of retinopathy in
Malaysian population. However, larger studies are necessary to
support and substantiate this study.
Table 1 Demographic data for healthy controls, and DNR and DR
groups
Demography
Healthy controls
(n[235)
DNR
(n[171)
DR
(n[171)
Sex (male/female) 198/144 100/71 98/73
Age (years) 55.265.0 59.269.6y 56.1610.1z
BMI (kg/m
2) 25.664.8 (n¼183) 27.264.4 26.465.3
HbA1c (%) 5.660.4 (n¼183) 7.961.8y 9.062.1yz
Total cholesterol (mmol/l) 3.860.6 (n¼183) 4.561.0y 4.961.6yz
Triglyceride (mmol/l) 1.861.3 (n¼183) 1.660.7 1.760.9
HDL-C (mmol/l) 1.060.3 (n¼183) 1.260.3y 1.360.3y
LDL-C (mmol/l) 2.160.5 (n¼183) 2.560.9y 2.861.3y
ALT (IU/l) 30e65* 37.8617.5 36.0618.6
AST (IU/l) 15e37* 22.0614.0 21.0614.3
SBP (mm Hg) 124.068.0 (n¼183) 136.5619.5y 141.0622.5y
DBP (mm Hg) 83.067.0 (n¼183) 79.0610.5y 80.1612.6
Diabetes duration (years) e 10.467.9 14.868.6z
Current smoker (yes/no) 43/192 29/142 14/157yz
Alcohol intake (yes/no) 70/165 24/147y 18/153y
Hypertension (yes/no) 11/224 134/37y 137/34y
Data are expressed as mean6SD.
Dichotomous variables are given in absolute numbers and tested with c
2 test.
*Normal value range provided
yp<0.05 versus healthy controls
zp<0.05 versus DNR.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index;
DBP, diastolic blood pressure; DNR, diabetic non-retinopathy; DR, diabetic retinopathy;
HbA1c, glycated haemoglobin; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-
density lipoprotein cholesterol; SBP, systolic blood pressure.
Table 2 Genotype distribution and allele frequency of 2245G/A polymorphisms in the groups studied
Clinical group
Genotype distribution
Allele
frequency (%)
p Value HWE GG GA AA G A
Control (n¼235) 209 (88.9) 26 (11.1) 0 (0.0) 94.5 5.5 e 0.81
DNR (n¼171) 143 (83.6) 28 (16.4) 0 (0.0) 91.8 8.2 NS 1.36
DR (n¼171) 119 (68.6) 52 (31.4) 0 (0.0) 84.8 15.2 <0.001 (<0.01*) 5.5
Data are reported as values with per cent in parentheses unless otherwise indicated.
*Compared with DNR.
DNR, diabetic non-retinopathy; DR, diabetic retinopathy; HWE, HardyeWeinberg equilibrium in c
2 value.
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